{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:13:14Z","timestamp":1780078394257,"version":"3.54.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471759"],"award-info":[{"award-number":["81471759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00270-020-02661-9","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T20:02:44Z","timestamp":1603137764000},"page":"271-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Kanglian","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"issue":"6","key":"2661_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","volume":"51","author":"EC Lazcano-Ponce","year":"2001","unstructured":"Lazcano-Ponce EC, Miquel JF, Mu\u00f1oz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349\u201364.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2661_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ijc.21683","volume":"118","author":"G Randi","year":"2006","unstructured":"Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591\u2013602.","journal-title":"Int J Cancer"},{"issue":"6","key":"2661_CR3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1572-0241.2000.02070.x","volume":"95","author":"S Sheth","year":"2000","unstructured":"Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"2661_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"2661_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-009-1055-0","volume":"65","author":"A Sharma","year":"2009","unstructured":"Sharma A, Mohanti B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2009;65(3):497.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"2661_CR6","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28(30):4581\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2661_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62(5):849\u201355.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2661_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/ijc.31144","volume":"142","author":"DH Ahn","year":"2018","unstructured":"Ahn DH, Reardon J, Ahn CW, et al. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2018;142(8):1671\u20135.","journal-title":"Int J Cancer"},{"issue":"6","key":"2661_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","volume":"99","author":"T Andr\u00e9","year":"2008","unstructured":"Andr\u00e9 T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862\u20137.","journal-title":"Br J Cancer"},{"issue":"3","key":"2661_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000339499","volume":"58","author":"SM Woo","year":"2012","unstructured":"Woo SM, Lee WJ, Han SS, et al. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. Chemotherapy. 2012;58(3):225\u201332.","journal-title":"Chemotherapy"},{"issue":"1","key":"2661_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4251\/wjgo.v12.i1.83","volume":"12","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Gunchick V, Mody K, et al. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World J Gastrointest Oncol. 2020;12(1):83\u201391.","journal-title":"World J Gastrointest Oncol"},{"key":"2661_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/OTT.S79316","volume":"8","author":"Q Zhao","year":"2015","unstructured":"Zhao Q, Qian S, Zhu L, et al. Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer. Onco Targets Ther. 2015;8:595\u2013600.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"2661_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","volume":"36","author":"S Rafi","year":"2013","unstructured":"Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440\u20138.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"2661_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.soc.2019.06.008","volume":"28","author":"S Mondaca","year":"2019","unstructured":"Mondaca S, Yarmohammadi H, Kemeny NE. Regional chemotherapy for biliary tract tumors and hepatocellular carcinoma. Surg Oncol Clin N Am. 2019;28(4):717\u201329.","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"2661_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1148\/radiol.2016160572","volume":"283","author":"X Wang","year":"2017","unstructured":"Wang X, Hu J, Cao G, et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma. Radiology. 2017;283(2):580\u20139.","journal-title":"Radiology"},{"issue":"8","key":"2661_CR16","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s10620-013-2624-y","volume":"58","author":"M Sinn","year":"2013","unstructured":"Sinn M, Nicolaou A, Gebauer B, et al. Hepatic arterial infusion with oxaliplatin and 5-FU\/folinic acid for advanced biliary tract cancer: a phase II study. Dig Dis Sci. 2013;58(8):2399\u2013405.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"2661_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4254\/wjh.v2.i5.192","volume":"2","author":"M Nishimura","year":"2010","unstructured":"Nishimura M. A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer. World J Hepatol. 2010;2(5):192\u20137.","journal-title":"World J Hepatol"},{"issue":"9","key":"2661_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589\u201395.","journal-title":"Ann Oncol"},{"issue":"10","key":"2661_CR19","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.jvir.2011.02.022","volume":"22","author":"X Wang","year":"2011","unstructured":"Wang X, Shah RP, Maybody M, et al. Cystic artery localization with a three-dimensional angiography vessel tracking system compared with conventional two-dimensional angiography. J Vasc Interv Radiol. 2011;22(10):1414\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"2661_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1471-2407-7-69","volume":"7","author":"B Hildebrandt","year":"2007","unstructured":"Hildebrandt B, Pech M, Nicolaou A, et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a phase II-study and historical comparison with the surgical approach. BMC Cancer. 2007;7:69\u201369.","journal-title":"BMC Cancer"},{"issue":"1","key":"2661_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40644-019-0202-z","volume":"19","author":"J Hu","year":"2019","unstructured":"Hu J, Zhu X, Wang X, Cao G, Wang X, Yang R. Evaluation of percutaneous unilateral trans-femoral implantation of side-hole port-catheter system with coil only fixed-catheter-tip for hepatic arterial infusion chemotherapy. Cancer Imag. 2019;19(1):15\u201315.","journal-title":"Cancer Imag"},{"issue":"1","key":"2661_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/01.RVI.0000052292.26939.59","volume":"14","author":"T Tanaka","year":"2003","unstructured":"Tanaka T, Arai Y, Fau-Inaba Y, Matsueda K, et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2003;14(1):63\u20138.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"2661_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.tvir.2007.08.007","volume":"10","author":"Y Arai","year":"2007","unstructured":"Arai Y, Takeuchi Y, Inaba Y, et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Tech Vasc Interv Radiol. 2007;10(1):30\u20137.","journal-title":"Tech Vasc Interv Radiol"},{"issue":"2","key":"2661_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2661_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.23781","volume":"111","author":"LM Boehm","year":"2015","unstructured":"Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213\u201320.","journal-title":"J Surg Oncol"},{"issue":"4","key":"2661_CR26","first-page":"677","volume":"17","author":"B Melichar","year":"2012","unstructured":"Melichar B, Ferko A, Krajina A, Rouskov\u00e1 L, et al. Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma. J BUON. 2012;17(4):677\u201383.","journal-title":"J BUON"},{"issue":"5","key":"2661_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3816\/CCC.2010.n.044","volume":"9","author":"H Nishiofuku","year":"2010","unstructured":"Nishiofuku H, Tanaka T, Aramaki T, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter. Retrosp Anal Clin Color Cancer. 2010;9(5):305\u201310.","journal-title":"Retrosp Anal Clin Color Cancer"},{"issue":"35","key":"2661_CR28","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1200\/JCO.2007.12.1764","volume":"25","author":"S Mocellin","year":"2007","unstructured":"Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649\u201354.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2661_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10637-007-9048-5","volume":"25","author":"C Carnaghi","year":"2007","unstructured":"Carnaghi C, Santoro A, Rimassa L, et al. The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study. Investig New Drugs. 2007;25(5):479\u201385.","journal-title":"Investig New Drugs"},{"issue":"6A","key":"2661_CR30","first-page":"743","volume":"20","author":"A Del Freo","year":"2006","unstructured":"Del Freo A, Fiorentini G, Sanguinetti F, Muttini MP, et al. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. Vivo. 2006;20(6A):743\u20136.","journal-title":"Vivo"},{"issue":"7","key":"2661_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953\u201360.","journal-title":"JAMA Oncol"},{"key":"2661_CR32","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00270-019-02406-3","volume":"43","author":"J Hu","year":"2020","unstructured":"Hu J, Bao Q, Cao G, et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization\/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. CardioVasc Interv Radiol. 2020;43:996\u20131005. https:\/\/doi.org\/10.1007\/s00270-019-02406-3.","journal-title":"CardioVasc Interv Radiol"},{"issue":"4","key":"2661_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/01.cad.0000198912.98442.cd","volume":"17","author":"B Qin","year":"2006","unstructured":"Qin B, Tanaka R, Shibata Y, et al. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. Anticancer Drugs. 2006;17(4):445\u201353.","journal-title":"Anticancer Drugs"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-020-02661-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-020-02661-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-020-02661-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T05:39:42Z","timestamp":1634621982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-020-02661-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1007\/s00270-020-02661-9","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this retrospective study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}